CJC-1295 in healthy adults — growth hormone and IGF-1 study
Journal of Clinical Endocrinology & Metabolism / PubMed
TL;DR
CJC-1295 produced prolonged, dose-dependent increases in GH and IGF-1 in healthy adults, with effects lasting days after injection.
Two randomized · double-blind · placebo-controlled dose-escalation trials
What was studied
The question.
The pharmacokinetics, growth-hormone response, IGF-1 response and short-term safety of long-acting CJC-1295 in healthy adults.
How it was conducted
The study design.
Healthy adults aged 21–61 received ascending single doses or repeated weekly/biweekly subcutaneous CJC-1295 or placebo. Researchers measured GH, IGF-1 and standard pharmacokinetic parameters over 28- and 49-day study periods.
What it found
Did it actually work?
- Mean GH concentrations increased roughly 2- to 10-fold for six days or more after a single injection.
- Mean IGF-1 increased about 1.5- to 3-fold for 9–11 days.
- The estimated half-life was approximately 5.8–8.1 days.
Why it matters
How to read this result.
It provides direct human evidence that long-acting CJC-1295 meaningfully changes the GH/IGF-1 axis.
Keep in mind
What the study does not prove.
- The study evaluated long-acting CJC-1295, not the shorter-acting 'CJC no DAC' / Mod GRF product commonly discussed online.
- It measured hormone responses rather than body-composition or performance outcomes.
Original source
Want to read the original?
We summarize the study here first. The original source is there when you want the full methods, statistics, tables and author discussion.
Open indexed study record